MA35015B1 - Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées - Google Patents

Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées

Info

Publication number
MA35015B1
MA35015B1 MA36289A MA36289A MA35015B1 MA 35015 B1 MA35015 B1 MA 35015B1 MA 36289 A MA36289 A MA 36289A MA 36289 A MA36289 A MA 36289A MA 35015 B1 MA35015 B1 MA 35015B1
Authority
MA
Morocco
Prior art keywords
dihydroimidazo
quinazolines
substituted
pharmaceutical composition
relates
Prior art date
Application number
MA36289A
Other languages
English (en)
Inventor
Ningshu Liu
Claudia Schneider
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35015(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35015B1 publication Critical patent/MA35015B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé de 2,3-dihydroimidazo[1,2-c]quinazoline ou d'une composition pharmac
MA36289A 2011-04-05 2012-03-29 Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées MA35015B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161142 2011-04-05
PCT/EP2012/055595 WO2012136549A1 (fr) 2011-04-05 2012-03-29 Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées

Publications (1)

Publication Number Publication Date
MA35015B1 true MA35015B1 (fr) 2014-04-03

Family

ID=45894478

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36289A MA35015B1 (fr) 2011-04-05 2012-03-29 Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées

Country Status (29)

Country Link
US (1) US10202385B2 (fr)
EP (1) EP2694069A1 (fr)
JP (1) JP6013446B2 (fr)
KR (1) KR102006033B1 (fr)
CN (1) CN103608018B (fr)
AP (1) AP3751A (fr)
AR (1) AR088730A1 (fr)
AU (2) AU2012238887A1 (fr)
BR (1) BR112013025517A2 (fr)
CA (1) CA2832120C (fr)
CL (1) CL2013002869A1 (fr)
CU (1) CU24349B1 (fr)
DO (1) DOP2013000224A (fr)
EA (1) EA027670B1 (fr)
EC (1) ECSP13013007A (fr)
GT (1) GT201300235A (fr)
IL (1) IL228435A0 (fr)
JO (1) JO3733B1 (fr)
MA (1) MA35015B1 (fr)
MX (1) MX2013011582A (fr)
MY (1) MY169532A (fr)
PE (1) PE20140571A1 (fr)
PH (1) PH12013502066A1 (fr)
SG (1) SG193577A1 (fr)
TN (1) TN2013000402A1 (fr)
TW (1) TWI639599B (fr)
UA (1) UA114177C2 (fr)
UY (1) UY33984A (fr)
WO (1) WO2012136549A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613743B1 (fr) 2008-01-04 2022-03-16 Intellikine, LLC Procédés de préparation de dérivés de 1h-pyrazolo[3,4-d]pyrimidin-4-amine
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2168583A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
EP2508525A1 (fr) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
MX2015014171A (es) 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
WO2015082376A2 (fr) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Utilisation d'inhibiteurs de pi3k
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
EP3018127A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
WO2016087490A1 (fr) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de la voie pi3k
KR101665234B1 (ko) * 2015-02-10 2016-10-12 순천향대학교 산학협력단 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
CA3016584A1 (fr) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3645005A1 (fr) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combinaison d'un inhibiteur de pi3k et d'un antagoniste du récepteur des androgènes
US11253522B2 (en) * 2018-04-28 2022-02-22 The Regents Of The University Of California Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
EP3843743A1 (fr) * 2018-08-28 2021-07-07 Bayer AS Combinaison d'inhibiteurs de pi3k et de conjugués de thorium ciblés

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1539891A (en) 1920-08-09 1925-06-02 Harry A Lewis Magnetic lifting device
US1450048A (en) 1921-09-24 1923-03-27 Mary S Patterson Nut lock
BE397809A (fr) 1932-08-25
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
WO2002069896A2 (fr) * 2001-03-01 2002-09-12 Northwest Hospital Apoptose de cellules cancereuses humaines induite par chimiotherapie et augmentee par connexine afin d'inhiber la proliferation de cellules cancereuses
EP1534073A4 (fr) * 2002-07-03 2005-09-14 Univ Columbia Procedes d'identification de modulateurs de l'apoptose a mediation assuree par mda-7
UA82205C2 (en) 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
JP5190233B2 (ja) 2006-09-01 2013-04-24 パナソニック株式会社 無線通信装置
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CA2713388C (fr) * 2008-01-14 2016-03-29 William Scott Derives de 2,3-dihydroimidazo [1,2-c] quinazoline a substitution sulfone utilises pour traiter des troubles hyperproliferants et des maladies associees a l'angiogenese
WO2009126172A1 (fr) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Résistance au polyphénone e en raison d'une expression de bcl2 accrue
CA2721665C (fr) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Composes comprenant un pharmacore anti-inflammatoire et procedes d'utilisation
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US8128386B2 (en) 2008-06-26 2012-03-06 Hamilton Sundstrand Corporation Variable flow pumping system
EP2168582A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
EP2168583A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
JP5336306B2 (ja) 2008-10-20 2013-11-06 信越化学工業株式会社 レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料
BRPI1010803A2 (pt) 2009-05-14 2018-06-12 Bayer Animal Health Gmbh "resposta imune aumentada na espécie aviária"
PH12012502069A1 (en) 2010-04-16 2013-02-04 Bayer Ip Gmbh Substituted 2,3-dihydroimidazo [1,2-c] quinazoline - containing combinations
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
UY33821A (es) 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
JP5884916B2 (ja) 2012-09-21 2016-03-15 トヨタ自動車株式会社 ハイブリッド車両用駆動装置

Also Published As

Publication number Publication date
SG193577A1 (en) 2013-10-30
TWI639599B (zh) 2018-11-01
AP2013007147A0 (en) 2013-09-30
JP6013446B2 (ja) 2016-10-25
ECSP13013007A (es) 2013-12-31
EP2694069A1 (fr) 2014-02-12
GT201300235A (es) 2014-08-27
KR102006033B1 (ko) 2019-07-31
US20140243295A1 (en) 2014-08-28
MY169532A (en) 2019-04-22
BR112013025517A2 (pt) 2016-12-27
KR20140025427A (ko) 2014-03-04
UA114177C2 (uk) 2017-05-10
TN2013000402A1 (en) 2015-03-30
PH12013502066A1 (en) 2020-10-19
CL2013002869A1 (es) 2014-07-18
CU24349B1 (es) 2018-06-05
UY33984A (es) 2012-10-31
AR088730A1 (es) 2014-07-02
CN103608018B (zh) 2017-06-30
TW201245202A (en) 2012-11-16
MX2013011582A (es) 2014-05-01
WO2012136549A1 (fr) 2012-10-11
AP3751A (en) 2016-07-31
CA2832120A1 (fr) 2012-10-11
EA027670B1 (ru) 2017-08-31
JO3733B1 (ar) 2021-01-31
CA2832120C (fr) 2020-10-27
AU2017203474A1 (en) 2017-06-08
CU20130134A7 (es) 2014-01-29
PE20140571A1 (es) 2014-05-19
IL228435A0 (en) 2013-12-31
US10202385B2 (en) 2019-02-12
EA201301106A1 (ru) 2014-03-31
AU2017203474B2 (en) 2019-03-21
AU2012238887A1 (en) 2013-10-10
CN103608018A (zh) 2014-02-26
NZ615502A (en) 2016-03-31
JP2014514297A (ja) 2014-06-19
DOP2013000224A (es) 2013-11-15

Similar Documents

Publication Publication Date Title
MA35015B1 (fr) Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CR20120333A (es) Isoquinolinonas y quinazolinonas substituidas.
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
EA201590534A1 (ru) Новые бициклические производные
EP2525659A4 (fr) Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MA35905B1 (fr) Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
IL225622A0 (en) Furo[3,2-d] pyrimidine compounds
CR20130045A (es) Compuestos terapéuticos
CR20130213A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogènesis
EA201490037A1 (ru) Антагонисты trpv4
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
EA201200218A1 (ru) Новые бициклические соединения мочевины
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS
EA201491153A1 (ru) КОМПОЗИЦИИ БУПРЕНОРФИНА И АНТАГОНИСТОВ μ-ОПИОИДНЫХ РЕЦЕПТОРОВ